
ROIV Stock Forecast & Price Target
ROIV Analyst Ratings
Bulls say
Roivant Sciences is a commercial-stage biopharmaceutical company with a positive outlook, as they have a strong pipeline of drug candidates, including VTAMA, Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others. Their recent clinical data for brepocitinib in cutaneous sarcoidosis and dermatomyositis has demonstrated potential for rapid and profound improvement and a significant market opportunity in these rare diseases. With a robust dataset and multiple catalysts on the horizon, the company is well-positioned for potential commercial success.
Bears say
Roivant Sciences is facing significant challenges in its drug development pipeline, as it has multiple drugs in various stages of development but lacks a track record of successful commercialization. In addition, the company's current financials are not strong, with low revenue and high non-GAAP loss per share. There is also a lack of clarity on the development plans for other assets, which could pose a risk to achieving the projected revenue estimate for 2036. Furthermore, Roivant may face tough competition in the commercial space from larger and more experienced players.
This aggregate rating is based on analysts' research of Roivant Sciences Ltd and is not a guaranteed prediction by Public.com or investment advice.
ROIV Analyst Forecast & Price Prediction
Start investing in ROIV
Order type
Buy in
Order amount
Est. shares
0 shares